Component
Midazolam plasma exposure / AUC
Midazolam plasma exposure / AUC. Species, exposure and limitations are retained in each linked claim.
2 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
Where it participates (unsigned role)
Sulforaphane alone did not change CYP3A activity in the cohort overall; a high-baseline subgroup showed increased midazolam exposure.
Experimental context and source evidence
- evidence_span
- {"source_cache": "artifacts/sulforaphane-research/23153560.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "e13099fede346485f6e468497ff2a4754fcae4d0203dde7f54fc9643c0599fec", "start_char": 0, "end_char": 1664, "text_sha256": "e13099fede346485f6e468497ff2a4754fcae4d0203dde7f54fc9643c0599fec"}
- experimental_model
- Three-arm randomized crossover trial
- exposure
- Rifampicin 300 mg/day, with or without sulforaphane 450 micromol/day for seven days; sulforaphane alone
- limitations
- Average null result does not exclude individual or other-drug interactions; high-baseline subgroup finding is not a dosing rule.
- nutrient_topic
- Sulforaphane research collection; topical membership is not evidence of a direct dietary effect. · Sulforaphane / SFN, stereochemistry specified per study
- organism
- Human, 24 healthy adults; humanized-PXR mouse parallel study
- plain_language
- An average null and an exploratory subgroup signal must both remain visible.
- primary_references
- [sulforaphane-p23153560] Sulforaphane is not an effective antagonist of the human pregnane X-receptor in vivo. (2013). https://pubmed.ncbi.nlm.nih.gov/23153560/ DOI: 10.1016/j.taap.2012.10.029
- tissue_or_cell_type
- CYP3A phenotyping with midazolam
Sulforaphane: formation, electrophile sensing and nutrient connections (2026-09-17) · lines 1269–1280
AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Three-arm randomized crossover trial · source_derived_draft · unverified_draft
### sulforaphane-cyp3a4-alone-null Sulforaphane alone did not change CYP3A activity in the cohort overall; a high-baseline subgroup showed increased midazolam exposure. Condition category: normal nutrient_topic: Sulforaphane research collection; topical membership is not evidence of a direct dietary effect. plain_language: An average null and an exploratory subgroup signal must both remain visible. organism: Human, 24 healthy adults; humanized-PXR mouse parallel study tissue_or_cell_type: CYP3A phenotyping with midazolam experimental_model: Three-arm randomized crossover trial limitations: Average null result does not exclude individual or other-drug interactions; high-baseline subgroup finding is not a dosing rule. exposure: Rifampicin 300 mg/day, with or without sulforaphane 450 micromol/day for seven days; sulforaphane alone evidence_span: {"source_cache": "artifacts/sulforaphane-research/23153560.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "e13099fede346485f6e468497ff2a4754fcae4d0203dde7f54fc9643c0599fec", "start_char": 0, "end_char": 1664, "text_sha256": "e13099fede346485f6e468497ff2a4754fcae4d0203dde7f54fc9643c0599fec"} [sulforaphane-p23153560] Sulforaphane is not an effective antagonist of the human pregnane X-receptor in vivo. (2013). https://pubmed.ncbi.nlm.nih.gov/23153560/ DOI: 10.1016/j.taap.2012.10.029
Complete structured claim and evidenceCoadministration did not prevent rifampicin-driven CYP3A induction; rifampicin alone lowered midazolam AUC by 70%.
Experimental context and source evidence
- evidence_span
- {"source_cache": "artifacts/sulforaphane-research/23153560.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "e13099fede346485f6e468497ff2a4754fcae4d0203dde7f54fc9643c0599fec", "start_char": 0, "end_char": 1664, "text_sha256": "e13099fede346485f6e468497ff2a4754fcae4d0203dde7f54fc9643c0599fec"}
- experimental_model
- Three-arm randomized crossover trial
- exposure
- Rifampicin 300 mg/day, with or without sulforaphane 450 micromol/day for seven days; sulforaphane alone
- limitations
- Average null result does not exclude individual or other-drug interactions; high-baseline subgroup finding is not a dosing rule.
- nutrient_topic
- Sulforaphane research collection; topical membership is not evidence of a direct dietary effect. · Sulforaphane / SFN, stereochemistry specified per study
- organism
- Human, 24 healthy adults; humanized-PXR mouse parallel study
- plain_language
- The proposed receptor-blocking effect from laboratory work did not carry through in the human trial.
- primary_references
- [sulforaphane-p23153560] Sulforaphane is not an effective antagonist of the human pregnane X-receptor in vivo. (2013). https://pubmed.ncbi.nlm.nih.gov/23153560/ DOI: 10.1016/j.taap.2012.10.029
- tissue_or_cell_type
- CYP3A phenotyping with midazolam
Sulforaphane: formation, electrophile sensing and nutrient connections (2026-09-17) · lines 1256–1267
AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Three-arm randomized crossover trial · source_derived_draft · unverified_draft
### sulforaphane-cyp3a4-rifampicin-null Coadministration did not prevent rifampicin-driven CYP3A induction; rifampicin alone lowered midazolam AUC by 70%. Condition category: normal nutrient_topic: Sulforaphane research collection; topical membership is not evidence of a direct dietary effect. plain_language: The proposed receptor-blocking effect from laboratory work did not carry through in the human trial. organism: Human, 24 healthy adults; humanized-PXR mouse parallel study tissue_or_cell_type: CYP3A phenotyping with midazolam experimental_model: Three-arm randomized crossover trial limitations: Average null result does not exclude individual or other-drug interactions; high-baseline subgroup finding is not a dosing rule. exposure: Rifampicin 300 mg/day, with or without sulforaphane 450 micromol/day for seven days; sulforaphane alone evidence_span: {"source_cache": "artifacts/sulforaphane-research/23153560.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "e13099fede346485f6e468497ff2a4754fcae4d0203dde7f54fc9643c0599fec", "start_char": 0, "end_char": 1664, "text_sha256": "e13099fede346485f6e468497ff2a4754fcae4d0203dde7f54fc9643c0599fec"} [sulforaphane-p23153560] Sulforaphane is not an effective antagonist of the human pregnane X-receptor in vivo. (2013). https://pubmed.ncbi.nlm.nih.gov/23153560/ DOI: 10.1016/j.taap.2012.10.029
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.